Table 3.
Cox regression analysis of specified markers in relation to PSA progression-free survival and prostate cancer-specific survival after androgen deprivation therapy of patients with metastases.
| PSA Progression | PC Specific Death | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | p-Value | HR | 95% CI | p-Value |
| (A) Univariate analyses | ||||||
| S100A9 mRNA | 2.4 | 1.0–5.7 | 0.045 | 6.7 | 1.4–32 | 0.016 |
| S100A12 mRNA | 3.2 | 1.3–7.9 | 0.010 | 3.1 | 0.8–12 | 0.100 |
| Monocyte count | 3.6 | 1.4–9.2 | 0.007 | 14 | 1.8–110 | 0.013 |
| Age | 1.0 | 1.0–1.1 | 0.186 | 1.1 | 1.0–1.1 | 0.059 |
| Gleason Score | 1.2 | 0.7–2.0 | 0.548 | 1.5 | 0.7–3.2 | 0.293 |
| PSA | 1.0 | 1.0–1.0 | 0.537 | 1.0 | 1.0–1.0 | 0.438 |
| (B) Multivariate analysis | ||||||
| S100A9 mRNA | 2.2 | 0.9–5.4 | 0.103 | 3.8 | 0.8–18 | 0.099 |
| Monocyte count | 3.4 | 1.3–8.7 | 0.011 | 10 | 1.2–82 | 0.031 |
| (C) Multivariate analysis | ||||||
| S100A12 mRNA | 2.9 | 1.1–7.6 | 0.027 | |||
| Monocyte count | 3.3 | 1.3–8.5 | 0.012 | |||
The S100A9, S100A12 mRNA levels and monocyte count were dichotomized by their median values and analyzed as categorical variables. Age, Gleason score and PSA were analyzed as continuous variables. Abbreviations: HR, hazard ratio; CI, confidence interval; PC, prostate cancer; PSA, prostate specific antigen.